DUBLIN, May 23, 2022--(BUSINESS WIRE)--The "Doxorubicin - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
Global Doxorubicin Market to Reach $1.3 Billion by 2026
The global market for Doxorubicin estimated at US$992.8 Million in the year 2020, is projected to reach a revised size of US$1.3 Billion by 2026, growing at a CAGR of 5.3% over the analysis period.
Growth in the global market is set to be driven by rising incidence of cancer, development of technologically advanced systems for drug delivery, increasing awareness levels among patients and rising disposable incomes of people. Doxorubicin use is anticipated to increase significantly for ovarian cancer treatment and treatment of AIDS-related Kaposi`s sarcoma following failure of systemic chemotherapy done previously. Increasing number of hepatocellular carcinoma and growing survival rates also constitutes a major growth driver.
Breast Cancer, one of the segments analyzed in the report, is projected to grow at a 5.1% CAGR to reach US$313.8 Million by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Lung Cancer segment is readjusted to a revised 6.9% CAGR for the next 7-year period.
This segment currently accounts for a 16.5% share of the global Doxorubicin market. Breast cancer represents a major category due to the constantly rising prevalence of breast cancer. Myocet, a non-pegylated liposomal doxorubicin, is approved in Canada and the European Union to treat metastatic breast cancer in combination with cyclophosphamide. Increasing incidence of lung cancer and rising awareness about available therapies is fueling demand for doxorubicin.
The U.S. Market is Estimated at $421.1 Million in 2021, While China is Forecast to Reach $106.6 Million by 2026
The Doxorubicin market in the U.S. is estimated at US$421.1 Million in the year 2021. The country currently accounts for a 40.56% share in the global market. China, the world`s second largest economy, is forecast to reach an estimated market size of US$106.6 Million in the year 2026 trailing a CAGR of 7.5% through the analysis period.
Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.9% and 5.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.3% CAGR while Rest of European market (as defined in the study) will reach US$113.8 Million by the end of the analysis period.
The US represents the largest regional market owing to the presence of a high number of people with different malignant tumors including lung, prostate, bladder, colon, breast and other malignancies. Use of the drug is high in the region, in mono as well as combination chemotherapies.
The well-developed healthcare infrastructure facilities in the country and high adoption of technologically advanced treatment methods for cancer are positioning the US as a major market for cancer therapies. Asia-Pacific represents another key market, due to rising cancer prevalence in the region, increasing awareness about various cancer therapies, and growing collaborations between private and public sectors to offer new cancer therapies in the region.
Ovarian Cancer Segment to Reach $179.7 Million by 2026
Liposomal delivery systems have considerably improved the safety and efficacy of chemotherapeutic agents, in comparison to non-liposomal formulations. The increasing prevalence of ovarian cancer spurs growing use of various forms of liposomal doxorubicin such as Caelyx/Doxil. In the global Ovarian Cancer segment, USA, Canada, Japan, China and Europe will drive the 3.4% CAGR estimated for this segment.
These regional markets accounting for a combined market size of US$122.9 Million in the year 2020 will reach a projected size of US$155.6 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$11.8 Million by the year 2026, while Latin America will expand at a 4.2% CAGR through the analysis period.
Key Topics Covered:
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
Cancer - An Insight
Chemotherapy: An Overview
An Introduction to Doxorubicin
Impact of Covid-19 and a Looming Global Recession
COVID-19 Impact on Global Doxorubicin Market
GLOBAL MARKET OVERVIEW
Global Doxorubicin Market Set to Witness Rapid Growth
US Dominates the Doxorubicin Market, Asia-Pacific to Witness Fastest Growth
Breast Cancer Constitutes the Largest Application for Doxorubicin
New Entrants Seek Opportunities
Recent Market Activity
2. FOCUS ON SELECT PLAYERS (Total 59 Featured)
Accord Healthcare Ireland Ltd
Cadila Healthcare Limited
Changzhou Kinyond Pharmaceutical Co., Ltd
Hikma Thymoorgan Pharmazie GmbH
Janssen-Cilag Pty Limited
Meiji Seika Pharma Co., Ltd.
MicroBiopharm Japan Co., Ltd.
Novartis International AG
Reddy's Laboratories Ltd.
Synbias Pharma AG
Teva Pharmaceutical Industries Ltd
TTY Biopharm Company Limited
3. MARKET TRENDS & DRIVERS
Rise in Cancer Incidence to Drive Market Growth
Liposomal Delivery Systems Offer Significant Benefits
A Review of Liposomal-Doxorubicin Preparations
Ageing Demographics to Drive Demand
Market to Gain from Rise in Number of Breast Cancer Cases
Select Doxorubicin Phase IV and Phase III Completed Clinical Trials for Breast Cancer with Results
Increasing Prevalence and Incidence of Lung Cancer to Push the Demand for Doxorubicin
Age-Standardized Lung Cancer Rates for Select Countries
Lymphoma, Leukemia, Bladder Cancer, & Kaposi Sarcoma: Other Major Growth Areas
Uptrend in Healthcare Spending Drives the Doxorubicin Demand
Cancer Research Spending Continues to Witness Growth
A Netherland's Based Research Team Suggests a Variant of Doxorubicin can be Made more Effective without the Heart Damage Side Effect (2020) (The Netherlands)
Researchers Develop Non-Toxic and Precise Nanoscale Technology for Oncology Drug Delivery
Studies Show Positive Effect of Quantum Dot Enabled Doxorubicin Delivery in Lung Cancer Treatment
Innovations in Cancer Drug Delivery: Key Factor in Product Differentiation
Peptoid-based Nanotubes Allow Precise, Targeted Delivery of Doxorucibin
Combination Therapy: A Double Whammy Success
4. GLOBAL MARKET PERSPECTIVE
III. REGIONAL MARKET ANALYSIS
For more information about this report visit https://www.researchandmarkets.com/r/vg3jh9
View source version on businesswire.com: https://www.businesswire.com/news/home/20220523005574/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900